Brokerages Set Omeros Co. (OMER) Price Target at $36.17
Omeros Co. (NASDAQ:OMER) has earned an average recommendation of “Buy” from the eleven ratings firms that are covering the stock, MarketBeat reports. Five investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $36.17.
A number of brokerages have recently commented on OMER. Cowen downgraded shares of Omeros from an “outperform” rating to a “market perform” rating in a research report on Thursday, November 2nd. Zacks Investment Research downgraded shares of Omeros from a “hold” rating to a “sell” rating in a report on Thursday, November 9th. HC Wainwright set a $30.00 target price on shares of Omeros and gave the stock a “buy” rating in a report on Wednesday, November 29th. Maxim Group reaffirmed a “buy” rating and set a $24.00 target price on shares of Omeros in a report on Friday, October 27th. Finally, Wedbush reaffirmed an “outperform” rating and set a $47.00 target price on shares of Omeros in a report on Friday, August 18th.
Omeros (OMER) traded down $0.55 during trading on Thursday, reaching $19.60. Omeros has a 1-year low of $8.71 and a 1-year high of $27.09. The company has a current ratio of 4.77, a quick ratio of 4.74 and a debt-to-equity ratio of 8.99.
Omeros (NASDAQ:OMER) last announced its quarterly earnings data on Thursday, November 9th. The biopharmaceutical company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.18. The firm had revenue of $21.66 million during the quarter, compared to the consensus estimate of $17.82 million. During the same period last year, the business earned ($0.34) EPS. The business’s revenue was up 91.9% on a year-over-year basis. equities research analysts predict that Omeros will post -0.98 EPS for the current year.
Institutional investors have recently modified their holdings of the business. AMP Capital Investors Ltd acquired a new position in shares of Omeros in the 3rd quarter valued at approximately $279,000. Stifel Financial Corp increased its position in Omeros by 10.7% during the 3rd quarter. Stifel Financial Corp now owns 394,428 shares of the biopharmaceutical company’s stock worth $8,522,000 after purchasing an additional 38,268 shares in the last quarter. Schwab Charles Investment Management Inc. increased its position in Omeros by 10.2% during the 3rd quarter. Schwab Charles Investment Management Inc. now owns 217,804 shares of the biopharmaceutical company’s stock worth $4,709,000 after purchasing an additional 20,139 shares in the last quarter. Wells Fargo & Company MN increased its position in Omeros by 13.8% during the 3rd quarter. Wells Fargo & Company MN now owns 42,144 shares of the biopharmaceutical company’s stock worth $911,000 after purchasing an additional 5,102 shares in the last quarter. Finally, First Interstate Bank acquired a new position in Omeros during the 3rd quarter worth approximately $108,000. Institutional investors and hedge funds own 49.85% of the company’s stock.
Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement.
Receive News & Ratings for Omeros Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros Co. and related companies with Analyst Ratings Network's FREE daily email newsletter.